Istradefylline – a first generation adenosine A2A antagonist for the treatment of Parkinson's disease
P Jenner, A Mori, SD Aradi… - Expert Review of …, 2021 - Taylor & Francis
Introduction It is now accepted that Parkinson's disease (PD) is not simply due to
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …
dopaminergic dysfunction, and there is interest in developing non-dopaminergic …
Pathophysiology of levodopa-induced dyskinesia: potential for new therapies
E Bezard, JM Brotchie, CE Gross - Nature Reviews Neuroscience, 2001 - nature.com
Involuntary movements—or dyskinesias—are a debilitating complication of levodopa
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
therapy for Parkinson's disease that is experienced by most patients. Despite the importance …
Distribution, biochemistry and function of striatal adenosine A2A receptors
P Svenningsson, C Le Moine, G Fisone… - Progress in …, 1999 - Elsevier
It is well known that the nucleoside adenosine exerts a modulatory influence in the central
nervous system by activating G protein coupled receptors. Adenosine A2A receptors, the …
nervous system by activating G protein coupled receptors. Adenosine A2A receptors, the …
A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice
JF Chen, Z Huang, J Ma, JM Zhu… - Journal of …, 1999 - Soc Neuroscience
Extracellular adenosine critically modulates ischemic brain injury, at least in part through
activation of the A1 adenosine receptor. However, the role played by the A2A receptor has …
activation of the A1 adenosine receptor. However, the role played by the A2A receptor has …
Cell type–specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs
HS Bateup, P Svenningsson, M Kuroiwa, S Gong… - Nature …, 2008 - nature.com
DARPP-32 is a dual-function protein kinase/phosphatase inhibitor that is involved in striatal
signaling. The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the …
signaling. The phosphorylation of DARPP-32 at threonine 34 is essential for mediating the …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum
Activation of adenosine A2A receptors (A2AR) has been shown to antagonize the function of
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …
D2 dopaminergic regulation of striatal γ‐aminobutyric acid (GABA)‐ergic output and, thus …
Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias
F Calon, M Dridi, O Hornykiewicz, PJ Bédard… - Brain, 2004 - academic.oup.com
Brain adenosine A2A receptors have recently attracted considerable attention because of
their interaction with the dopaminergic system and as potential targets for Parkinson's …
their interaction with the dopaminergic system and as potential targets for Parkinson's …
Adenosine, adenosine A2A antagonists, and Parkinson's disease
P Jenner, A Mori, R Hauser, M Morelli… - Parkinsonism & related …, 2009 - Elsevier
Adenosine derived from the degradation of ATP/AMP functions as a signalling molecule in
the nervous system through the occupation of A1, A2, and A3 adenosine receptors …
the nervous system through the occupation of A1, A2, and A3 adenosine receptors …
Available and emerging treatments for Parkinson's disease: a review
P Hickey, M Stacy - Drug design, development and therapy, 2011 - Taylor & Francis
Parkinson's disease is a commonly encountered neurodegenerative disorder primarily
found in aged populations. A number of medications are available to control symptoms …
found in aged populations. A number of medications are available to control symptoms …